Fagron vs Hims & Hers

Vial Take

Both serve TRT patients and carry clean federal records across FDA, OIG, DEA, and HIPAA, so the foundational compliance baseline is solid on either side. Hims & Hers pulls ahead on third-party credentialing with LegitScript certification and a 12-point trust score advantage, while Fagron's lack of that certification and undisclosed pharmacy chain means fewer external checkpoints if you're trying to verify what's actually in your compounds. Where Fagron earns its own credibility is as a named supply-chain partner for higher-transparency platforms like Marek Health, so if you're already on a clinical platform sourcing from Fagron, you're getting indirect vetting that a direct Hims & Hers TRT patient doesn't automatically have on the compounding side.

Biggest Differences

1. 1
   Pharmacy disclosure
   Hims & Hers publishes its compounding partner (Hims & Hers), so you can verify the supply chain; Fagron does not name a pharmacy partner publicly.
2. 2
   LegitScript certification
   Hims & Hers holds LegitScript certification (the credential required to advertise on Google and Meta); Fagron does not.
3. 3
   Trust Score gap (12 points)
   Hims & Hers scores 88/100 to Fagron's 76/100, a 12-point spread driven by the differences below.